Dr. Laura Jean Johnston, MD is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Palo Alto, CA
She has not yet shared a personalized biography with Doctor.com.
| University | Degree | Focus | Graduated |
|---|---|---|---|
| University of Minnesota Medical School | Medical Degree | 1982 |
| Institution | Focus | Year |
|---|---|---|
| Internship - Ucsf Medical Center | 1990 | |
| Residency - UCSF Medical Center | 1992 | |
| Residency - Aultman Hospital/NEOMED Program | Not Specified | |
| Fellowship - Ucsf Medical Center | 1995 |
| Position | Organization | Time |
|---|---|---|
| Associate Professor of Medicine (Blood and Marrow Transplantation) | the Stanford University Medical Center | Present |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
| Other Publication | NEW ENGLAND JOURL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
| Other Publication | BLOOD | Prophylactic rituximab after allogeneic transplantation decreases B | 2012 |
| Other Publication | BONE MARROW TRANSPLANTATION | Sirolimus and mycophenolate mofetil as GVHD prophylaxis in myeloablative | 2012 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy | 2012 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Adoptive Immunotherapy with Cytokine | 2011 |
| Other Publication | BLOOD | A phase 1 study of imatinib for corticosteroid-dependent | 2011 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Early CMV Viremia Is Associated with Impaired Viral Control following Nonmyeloablative | 2011 |
| Other Publication | CORNEA | Long-term Clinical Course of Dry Eye in Patients With Chronic Graft | 2011 |
| Other Publication | BONE MARROW TRANSPLANTATION | Long-term outcomes in patients with high | 2011 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Phase I/II Trial of GN-BVC | 2010 |
| Other Publication | BONE MARROW TRANSPLANTATION | Long-term follow-up of patients with diffuse large B-cell non-Hodgkin's lymphoma receiving purged | 2010 |
| Other Publication | BLOOD | TLI and ATG conditioning with low risk of graft-versus | 2009 |
| Other Publication | BONE MARROW TRANSPLANTATION | High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors | 2009 |
| Other Publication | BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | Acute graft-versus-host disease | 2008 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | High-dose carmustine, etoposide | 2006 |
| Other Publication | NEW ENGLAND JOURNAL OF MEDICINE | Protective conditioning for acute graft-versus-host disease | 2005 |
| Other Publication | TRANSPLANT INFECTIOUS DISEASE | Treatment of verruca vulgaris with topical cidofovir in an immunlocompromised patient | 2005 |
| Other Publication | BLOOD | Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell | 2005 |
| Other Publication | EXPERIMENTAL HEMATOLOGY | CD34, CD49 and CD8 cell doses do not influence engraftment | 2005 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease | 2005 |
| Other Publication | CANCER CHEMOTHERAPY AND PHARMACOLOGY | Treatment of acute leukemia with idarubicin | 2004 |
| Other Publication | Blood | Rituximab as adjuvant to high-dose therapy | 2003 |
| Other Publication | BLOOD | Comparison of chronic graft-versus | 2002 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | High-dose therapy and autologous hematopoietic | 2001 |
Dr. Laura Jean Johnston, MD has not yet indicated the hospitals that she is affiliated with.
Accepts New Patients: Yes
Dr. Laura Jean Johnston, MD has not yet listed the medications that she commonly prescribes.
Dr. Laura Jean Johnston, MD has not yet added any information about her practice's billing policies and payment options.
